Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.56 |
| ▸ | HTR2A | P28223 | 8/20 | 0.56 |
| ▸ | HTR2C | P28335 | 8/20 | 0.56 |
| ▸ | HTR2B | P41595 | 8/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14950126 | 0.88 | DRD2 (0.62) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL11090923 | 0.88 | CYP2A6 (0.53) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL20133218 | 0.85 | CRBN (0.49) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL30707960 | 0.81 | CYP19A1 (0.53) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL1332811 | 0.81 | CYP19A1 (0.53) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL385513 | 0.81 | CYP19A1 (0.53) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL11819054 | 0.81 | CYP19A1 (0.53) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL1094690 | 0.81 | CYP19A1 (0.53) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL7938960 | 0.80 | ACHE (0.53) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL25001243 | 0.79 | ACHE (0.66) | DRD2HTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064060-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | DRD2 3539/4885HTR2A 4750/4885HTR2C 4819/4885 |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | DRD2 3539/4885HTR2A 4750/4885HTR2C 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.